Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma

Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Sae-Byeol Choi, Kwang Hun Lee, Mi Sook Park, Jun Yong Park, Do Yun Lee, Kwang Hyub Han, Kyung Sik Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. Methods: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. Results: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355). Conclusion: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.

Original languageEnglish
Pages (from-to)184-191
Number of pages8
JournalOncology
Volume81
Issue number3-4
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Fluorouracil
Cisplatin
Hepatocellular Carcinoma
Recurrence
Drug Therapy
Liver
Control Groups
Portal Vein
Cause of Death
Neoplasms
Survival Rate
Survival

Keywords

  • Adjuvant therapy
  • Hepatic arterial infusional chemotherapy
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. / Kim, Do Young; Ahn, Sang Hoon; Kim, Seung Up; Choi, Sae-Byeol; Lee, Kwang Hun; Park, Mi Sook; Park, Jun Yong; Lee, Do Yun; Han, Kwang Hyub; Kim, Kyung Sik.

In: Oncology, Vol. 81, No. 3-4, 01.12.2011, p. 184-191.

Research output: Contribution to journalArticle

Kim, DY, Ahn, SH, Kim, SU, Choi, S-B, Lee, KH, Park, MS, Park, JY, Lee, DY, Han, KH & Kim, KS 2011, 'Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma', Oncology, vol. 81, no. 3-4, pp. 184-191. https://doi.org/10.1159/000333827
Kim, Do Young ; Ahn, Sang Hoon ; Kim, Seung Up ; Choi, Sae-Byeol ; Lee, Kwang Hun ; Park, Mi Sook ; Park, Jun Yong ; Lee, Do Yun ; Han, Kwang Hyub ; Kim, Kyung Sik. / Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. In: Oncology. 2011 ; Vol. 81, No. 3-4. pp. 184-191.
@article{0eed6a8fad7a401fa3a1bce0b986384f,
title = "Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma",
abstract = "Objectives: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. Methods: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. Results: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5{\%}) and 24 control patients (38.7{\%}; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6{\%}) and 7 control patients (38.8{\%}; p = 0.912). The 2-year recurrence rate was 9.1{\%} in the adjuvant group and 4.2{\%} in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3{\%} in the adjuvant group and 68.3{\%} in the control group (p = 0.355). Conclusion: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.",
keywords = "Adjuvant therapy, Hepatic arterial infusional chemotherapy, Hepatocellular carcinoma",
author = "Kim, {Do Young} and Ahn, {Sang Hoon} and Kim, {Seung Up} and Sae-Byeol Choi and Lee, {Kwang Hun} and Park, {Mi Sook} and Park, {Jun Yong} and Lee, {Do Yun} and Han, {Kwang Hyub} and Kim, {Kyung Sik}",
year = "2011",
month = "12",
day = "1",
doi = "10.1159/000333827",
language = "English",
volume = "81",
pages = "184--191",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3-4",

}

TY - JOUR

T1 - Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Kim, Seung Up

AU - Choi, Sae-Byeol

AU - Lee, Kwang Hun

AU - Park, Mi Sook

AU - Park, Jun Yong

AU - Lee, Do Yun

AU - Han, Kwang Hyub

AU - Kim, Kyung Sik

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Objectives: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. Methods: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. Results: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355). Conclusion: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.

AB - Objectives: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. Methods: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. Results: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355). Conclusion: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.

KW - Adjuvant therapy

KW - Hepatic arterial infusional chemotherapy

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84255170904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84255170904&partnerID=8YFLogxK

U2 - 10.1159/000333827

DO - 10.1159/000333827

M3 - Article

C2 - 22067673

AN - SCOPUS:84255170904

VL - 81

SP - 184

EP - 191

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3-4

ER -